ProLynx LLC, founded in 2009, is developing a technology platform that overcomes major limitations of releasable linkers currently used in drug conjugation. The technology uses sets of novel linkers that cleave at different, pre-programmed rates to allow the controlled, predictable and sustained release of native, active drugs – peptides, proteins and small molecules – from circulating and fixed macromolecular conjugates. 

Using our technology, we can sustain desired steady-state levels of such drugs for predictable periods that can be specifically tailored for a particular drug.   

"Everything should be made as simple as possible, but not simpler."
Albert Einstein